Credit Suisse analyst Vamil Divan maintained a Buy rating on Pfizer (PFE) yesterday and set a price target of $48. The company’s shares opened today at $43.07.
According to TipRanks.com, Divan has 0 stars on 0-5 star ranking scale with an average return of -3.6% and a 43.0% success rate. Divan covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Ironwood Pharma, and Eli Lilly & Co.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $47.14 average price target, a 9.4% upside from current levels. In a report issued on June 4, Morgan Stanley also resumed coverage with a Buy rating on the stock with a $48 price target.
See today’s analyst top recommended stocks >>
Based on Pfizer’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $13.12 billion and net profit of $3.88 billion. In comparison, last year the company earned revenue of $12.91 billion and had a net profit of $3.56 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
